By contrast, primary prostate cancer (PCa) sequences in The Cancer Genome Atlas (TCGA) revealed biallelic CDK12 alterations in only 6/498 cases (1.2%)—a finding indicating enrichment of CDK12 inactivation in metastatic disease.18 This evidence concerns the gene CDK12 and prostate carcinoma.